Welcome to the Most Comprehensive Forum for Microbiome Drug Developers
2021 promises to be a pivotal year for the microbiome community, with an abundance of positive news coming from the industry already this year! With recent late-stage clinical successes from Seres Therapeutics and Rebiotix, a Ferring Company, the first and long-awaited approval of a microbiome therapeutic is within touching distance!
Microbiome drug developers are encountering several challenges in understanding the function of the microbiome, achieving clinical success, effectively scaling up production, and stratifying patients for improved clinical successes. Now, the community must gather to:
- Improve understanding of the mechanistic function of the microbiome, focusing on outlining specific modes of action of live biotherapeutic and small molecule approaches
- Optimize clinical outcomes with improved trial design and leveraging previous successes, as well as through stratifying patients through clinically relevant biomarkers
- Achieve a consistent production supply, with purity and scalability at the forefront of our minds to address the growing production demands
Access the official 2021 agenda to see the topics that will be addressed
4 Areas that Define the Drug Development Summit
Understanding Microbiome Function & Pre-Clinical Development
Clinical Translation & Manufacturing of Microbiome Therapeutics
Microbiome Biomarkers, Patient Stratification & Diagnostics
Pre-Conference Immune-Disease Focus Day
Uncover microbiome functionality, discover the appraoches to identifying new therapeutic targets, and advance novel therapeutics from discovery through pre-clinical development
Hear from subject experts to overcome key clinical development challenges, and to optimize CMC and product quality, to drive your products through the clinic faster
Discover approaches to identifying microbiome biomarkers with clinical utility, and uncover how biomarkers are being used to improve stratification, in order to improve the outcomes of your clinical studies
Explore the latest scientific research understanding the role of the microbiome in immune-mediated diseases to better develop microbiome candidates focused on immuno-oncology and IBD
Hear What the Microbiome Community Says
"By bringing together experts in the field who are approaching this challenge from
every angle, we can synergistically accelerate unleashing the complete therapeutic
power of the microbiome”
Emily Drabant Conley, Federation Bio
“I am excited about the opportunity to discuss openly with key stakeholders in our field the next frontiers we collectively see and the most critical challenges we face in translating our research to the clinic”
Stephanie Culler, Persephone Biosciences
